A multicenter randomized controlled clinical trial confirms that both chemical-first and electrical-first approaches are effective strategies for acute atrial fibrillation; however, an ...
Pharmacologic cardioversion followed by electrical cardioversion and electrical cardioversion only were found to be safe and effective in patients presenting to the emergency department with recent ...
Nicholas P. Gall, M.Sc., M.D., M.R.C.P.; Francis D. Murgatroyd, M.A., F.R.C.P., F.A.C.C. From these and subsequent studies, it became clear that cardioversion was ...
Please provide your email address to receive an email when new articles are posted on . Sinus rhythm was restored in an effective, safe and rapid manner using drug-shock or shock-only strategies among ...
The drug-shock strategy was more effective for patients experiencing atrial fibrillation for the first time and for patients younger than 70 years, the researchers said. Both the anti-arrhythmia drug ...
Bayer begins phase II study of investigational GIRK4 inhibitor in patients with atrial fibrillation: Berlin Thursday, September 10, 2026, 10:00 Hrs [IST] Bayer announced the initi ...
VANCOUVER, Cardiome Pharma Corp. today announced that an independent study conducted by investigators at the University of Leipzig Heart Center,Germany, found that intravenous vernakalant facilitated ...
Patients with atrial fibrillation (AF) who need anticoagulation before undergoing electrical correction of their abnormal heartbeat (cardioversion) may benefit from treatment with edoxoban - a ...
Pharmacological- and electrical-first cardioversion worked similarly well for treating acute atrial fibrillation (Afib) in the emergency department, according to the Canadian RAFF2 trial. The 204 ...
Introduction Improving Immediate Cardioversion Success Maintenance of Sinus Rhythm Following Cardioversion Future Developments/Research References Maintenance of Sinus Rhythm Following Cardioversion ...
A placebo-controlled, parallel-group, double blind, randomized, multi-cohort Phase II study will investigate efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of BAY 3670549 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results